Skip to main content

Advertisement

SpringerLink
Log in

New trends in the treatment of undifferentiated carcinomas of the thyroid

  • Current Concepts in Endocrine Surgery
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Introduction

Malignant tumours of the thyroid are generally classified as either well-differentiated thyroid carcinoma, which is composed of papillary and follicular carcinoma, or undifferentiated/anaplastic thyroid carcinoma (ATC). ATC is not only the most lethal disease in the field of endocrine surgery but also one of the most aggressive tumours characterized by an almost invariable fatal outcome, which only very rarely exceeds a 1-year course.

Discussion

The impact of surgical resection in association with external beam radiation on ATC outcome has been extensively investigated also in studies based on multicentric database, and there is a general agreement on the significance of a complete resection of the tumour. It has been difficult up to now to collect data regarding chemotherapy adjuvant treatment. In spite of the lack of an extensive review about the results of this kind of treatment by itself or as part of a multimodal approach, it seems that among the several chemotherapy agents experienced, none proved to influence significantly ATC prognosis. Neither doxorubicin (the most commonly used) nor other drugs, such as cisplatin, bleomycin, fluorouracil or cyclophosphamide, showed any real efficacy in controlling the disease.

Conclusion

The most recent development in this field seems to be represented by the possibility offered by PPARg agonists; even more promising might be the use of adenovirus-mediated p53 tumour suppressor gene therapy or BMP-7. All these new therapies need further confirmation coming from ongoing clinical trials such as those involving the use of vascular and growth factor-targeted agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Shaha R (2004) Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 114:393–402

    Article  PubMed  Google Scholar 

  2. Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849–1855

    Article  PubMed  CAS  Google Scholar 

  3. Carcangiu ML, Zampi G, Rosai J et al (1984) Poorly differentiated (“insular”) thyroid carcinoma: a reinterpretation of Langhans’ “wuchernde Struma.” Am J Surg Pathol 8:655–668

    Article  PubMed  CAS  Google Scholar 

  4. Nishida T, Katayama S, Tsujimoto M et al (1999) Clinicopathological significance of poorly differentiated thyroid carcinoma. Am J Surg Pathol 23:205–211

    Article  PubMed  CAS  Google Scholar 

  5. Sobrinho-Simoes M, Sambade C, Fonseca E et al (2002) Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol 10:123–131

    PubMed  Google Scholar 

  6. Pellegriti G, Giuffrida D, Scollo C et al (2002) Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis. Cancer 95:2076–2085

    Article  PubMed  Google Scholar 

  7. Sasaki A, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S (1996) Insular component as a risk factor of thyroid carcinoma. Pathol Int 46:939–946

    Article  PubMed  CAS  Google Scholar 

  8. Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79:564–573

    Article  PubMed  CAS  Google Scholar 

  9. Hundahl SA, Fleming ID, Fremgen AM, Manck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 2638–2648

  10. Kitamura Y, Shimizu K, Nagahama M et al (1999) Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 84:4043–4049

    Article  PubMed  CAS  Google Scholar 

  11. Nel CJ, van Heerden JA, Goellner JR et al (1985) Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc 60:51–58

    PubMed  CAS  Google Scholar 

  12. Tan RK, Finley RK III, Driscoll D et al (1995) Anaplastic of the thyroid: a 24-year experience. Head Neck 17:41–48

    Article  PubMed  CAS  Google Scholar 

  13. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Mc Millan A (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330–1335

    Article  PubMed  Google Scholar 

  14. Ain KB (1998) Anaplastic thyroid carcinoma: behaviour, biology and therapeutic approaches. Thyroid 8:715–726

    PubMed  CAS  Google Scholar 

  15. Holting T, Moller P, Tschahargane C, Meybier H, Buhr H, Herfarth C (1990) Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg 14:291–295

    Article  PubMed  CAS  Google Scholar 

  16. Carty SE (2001) Anaplastic thyroid cancer. In: Doherty G, Skogeid B (eds) Surgical Endocrinology. Lippincott Williams & Wilkins, Philadelphia, pp 127–134

    Google Scholar 

  17. Tan RK, Finley RK III, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP (1995) Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 17:41–48

    Article  PubMed  CAS  Google Scholar 

  18. Giuffrida D, Gharib D (2000) Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 127–134

  19. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617–622

    Article  PubMed  CAS  Google Scholar 

  20. Pacheco-Ojeda LA, Marinez AL, Alvarez M (2001) Anaplastic thyroid carcinoma in Ecuador: analysis of prognostic factors. Int Surg 86:117–121

    PubMed  CAS  Google Scholar 

  21. Busnardo B, Daniele O, Pellizzo MR et al (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: a study on 39 patients. J Endocrinol Investig 23:755–761

    CAS  Google Scholar 

  22. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57–64

    Article  PubMed  Google Scholar 

  23. Haigh PI, Ituarte PH, Wu HS et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335–2342

    Article  PubMed  CAS  Google Scholar 

  24. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A (2001) Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 27:260–264

    Article  PubMed  CAS  Google Scholar 

  25. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, Schlumberger M (2004) Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60(4):1137–1143, Nov 15

    Article  PubMed  Google Scholar 

  26. Haddad R, Mahadevan A, Posner MR, Sullivan C (2005) Long-term survival with adjuvant carboplatin, paclitaxel and radiation therapy in anaplastic cancer. Am J Clin Oncol 28(1):104, Feb

    Article  PubMed  Google Scholar 

  27. Mc Iver B, Hay ID, Giuffrida DF et al (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028–1034

    Article  Google Scholar 

  28. Junor EJ, Paul J, Reed NS, et al (1992) Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 18:83–88

    PubMed  CAS  Google Scholar 

  29. Kihara M, Miyauchi A, Yamauchi A, Yokomise H (2004) Prognostic factors of anaplastic thyroid carcinoma. Surg Today 34:394–398

    Article  PubMed  Google Scholar 

  30. Cobin RH, Gharib H, Berman DAL (2001) AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid cancer. Endocr Pract 7:203–220

    Google Scholar 

  31. Hotling T, Maybier H, Buhr H (1990) Status of tracheotomy in treatment of the respiratory emergency in anaplastic thyroid cancer. Wien Klin Wochenschr 102:264–266

    Google Scholar 

  32. Kobayashi T, Asakawa H, Umeshita K et al (1996) Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 18:36–41

    Article  PubMed  CAS  Google Scholar 

  33. Heron DE, Karimpour S, Grigsby PW (2002) Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol 25:442–446

    Article  PubMed  Google Scholar 

  34. Lo CY, Lam KY, Wan KY (1999) Anaplastic carcinoma of the thyroid. Am J Surg 77:337–339

    Article  Google Scholar 

  35. Tennvall J, Lundell G, Wahlberg P et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848–1853

    Article  PubMed  CAS  Google Scholar 

  36. Nilsson O, Lindeberg J, Zedenius J et al (1998) Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 22:725–730

    Article  PubMed  CAS  Google Scholar 

  37. Simpson WJ (1980) Anaplastic thyroid carcinoma: a new approach. Can J Surg 23:25–27

    PubMed  CAS  Google Scholar 

  38. Wong CS, Van Dyk J, Simpson WJ (1991) Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 20:3–9

    Article  PubMed  CAS  Google Scholar 

  39. Levendag PC, De Porre PM, van Putten WL (1993) Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26:125–128

    PubMed  CAS  Google Scholar 

  40. Mitchell G, Huddart R, Harmer C (1999) Phase II evaluation of high-dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 50:33–38

    Article  PubMed  CAS  Google Scholar 

  41. Kim JH, Leeper RD (1983) Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adriamycin and radiation therapy. A new approach. Cancer 52:954–957

    Article  PubMed  CAS  Google Scholar 

  42. Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372–2375

    Article  PubMed  CAS  Google Scholar 

  43. Asakawa H, Kobayashi T, Komoike Y et al (1997) Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 17:2757–2762

    PubMed  CAS  Google Scholar 

  44. Pacini F, Vitti P, Martino E et al (1984) Treatment of refractory thyroid cancer with adriamycin. Drugs Exp Clin Res 10:911–915

    Google Scholar 

  45. Shimaoka K, Schoenfeld DA, DeWys WD et al (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160

    Article  PubMed  CAS  Google Scholar 

  46. Chemotherapy Committee, the Japanese Society of Thyroid Surgery (1995) Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte colony-stimulating factor support. Jpn J Clin Oncol 25:203–207

    Google Scholar 

  47. Auersperg M, Us-Krasovec M, Petric G, Pogacnik A, Besic N (1990) Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 102:267–270

    PubMed  CAS  Google Scholar 

  48. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D (1991) Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67:564–566

    Article  PubMed  CAS  Google Scholar 

  49. Ain KB, Egorin MJ, DeSimone PA (2001) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594

    Article  Google Scholar 

  50. Grommes C et al (2004) Antineoplastic effects of peroxisome proliferator-activated receptor-gamma agonists. Lancet Oncol 5:419–429

    Article  PubMed  CAS  Google Scholar 

  51. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E (2006) Interferon-{gamma}-inducible {alpha}-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor-{gamma} agonists. J Clin Endocrinol Metab 91(2):614–620

    Article  PubMed  CAS  Google Scholar 

  52. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T (2001) Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86(5):2170–2177

    Article  PubMed  CAS  Google Scholar 

  53. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR (2004) Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 3(8):1011–1020

    PubMed  CAS  Google Scholar 

  54. Philips JC, Petite C, Willi JP, Buchegger F, Meier CA (2004) Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun 25(12):1183–1186

    Article  PubMed  CAS  Google Scholar 

  55. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH (2005) Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15(3):222–231

    Article  PubMed  CAS  Google Scholar 

  56. Frohlich E, Machicao F, Wahl R (2005) Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 12(2):291–303

    Article  PubMed  CAS  Google Scholar 

  57. Hayashi N, Nakamori S, Hiraoka N, Tsujie M, Xundi X, Takano T, Amino N, Sakon M, Monden M (2004) Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. Int J Oncol 24 (1):89–95

    PubMed  CAS  Google Scholar 

  58. Chung SH, Onoda N, Ishikawa T, Ogisawa K, Takenaka C, Yano Y, Hato F, Hirakawa K (2002) Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res 93:1358–1365

    PubMed  CAS  Google Scholar 

  59. Davies GF, Roesler WJ, Juurlink BH, Harkness TA (2005) Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma 46(8):1199–1206

    Article  PubMed  CAS  Google Scholar 

  60. Kanbe E, Abe A, Towatari M, Kawabe T, Saito H, Emi N (2003) DR1-like element in human topoisomerase II alpha gene involved in enhancement of etoposide-induced apoptosis by PPARgamma ligand. Exp Hematol 31(4):300–308

    Article  PubMed  CAS  Google Scholar 

  61. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T (1998) Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83:2516–2522

    Article  PubMed  CAS  Google Scholar 

  62. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M (2000) Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081–4086

    Article  PubMed  CAS  Google Scholar 

  63. Franzen A, Heldin NE (2001) BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun 285:773–781

    Article  PubMed  CAS  Google Scholar 

  64. Kotchetkov R, Cinatl J, Krivtchik AA, Vogel JU, Matousek J, Pouckova P, Kornhuber B, Schwabe D, Cinatl J Jr (2001) Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res 21:1035–1042

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Pisa, Pisa, Italy

    Paolo Miccoli, Gabriele Materazzi, Erica Panicucci, Gianluca Frustaci & Piero Berti

  2. Department of Internal Medicine, University of Pisa, Pisa, Italy

    Alessandro Antonelli

Authors
  1. Paolo Miccoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriele Materazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Antonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erica Panicucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gianluca Frustaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Piero Berti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriele Materazzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miccoli, P., Materazzi, G., Antonelli, A. et al. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch Surg 392, 397–404 (2007). https://doi.org/10.1007/s00423-006-0115-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-006-0115-8

Keywords

Search

Navigation